240 related articles for article (PubMed ID: 22339355)
1. ATP citrate lyase inhibitors as novel cancer therapeutic agents.
Zu XY; Zhang QH; Liu JH; Cao RX; Zhong J; Yi GH; Quan ZH; Pizzorno G
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):154-67. PubMed ID: 22339355
[TBL] [Abstract][Full Text] [Related]
2. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
Granchi C
Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
[TBL] [Abstract][Full Text] [Related]
3. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.
Khwairakpam AD; Shyamananda MS; Sailo BL; Rathnakaram SR; Padmavathi G; Kotoky J; Kunnumakkara AB
Curr Drug Targets; 2015; 16(2):156-63. PubMed ID: 25537655
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.
Koerner SK; Hanai JI; Bai S; Jernigan FE; Oki M; Komaba C; Shuto E; Sukhatme VP; Sun L
Eur J Med Chem; 2017 Jan; 126():920-928. PubMed ID: 27997879
[TBL] [Abstract][Full Text] [Related]
5. mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.
Chen Y; Qian J; He Q; Zhao H; Toral-Barza L; Shi C; Zhang X; Wu J; Yu K
Oncotarget; 2016 May; 7(18):25224-40. PubMed ID: 27015560
[TBL] [Abstract][Full Text] [Related]
6. An allosteric mechanism for potent inhibition of human ATP-citrate lyase.
Wei J; Leit S; Kuai J; Therrien E; Rafi S; Harwood HJ; DeLaBarre B; Tong L
Nature; 2019 Apr; 568(7753):566-570. PubMed ID: 30944472
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
[TBL] [Abstract][Full Text] [Related]
8. The lipogenesis pathway as a cancer target.
Abramson HN
J Med Chem; 2011 Aug; 54(16):5615-38. PubMed ID: 21726077
[No Abstract] [Full Text] [Related]
9. A role for ATP-citrate lyase, malic enzyme, and pyruvate/citrate cycling in glucose-induced insulin secretion.
Guay C; Madiraju SR; Aumais A; Joly E; Prentki M
J Biol Chem; 2007 Dec; 282(49):35657-65. PubMed ID: 17928289
[TBL] [Abstract][Full Text] [Related]
10. ATP citrate lyase: A central metabolic enzyme in cancer.
Icard P; Wu Z; Fournel L; Coquerel A; Lincet H; Alifano M
Cancer Lett; 2020 Feb; 471():125-134. PubMed ID: 31830561
[TBL] [Abstract][Full Text] [Related]
11. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Burke AC; Huff MW
Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
[TBL] [Abstract][Full Text] [Related]
12. Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening.
Jernigan FE; Hanai JI; Sukhatme VP; Sun L
Bioorg Med Chem Lett; 2017 Feb; 27(4):929-935. PubMed ID: 28129980
[TBL] [Abstract][Full Text] [Related]
13. The vital role of ATP citrate lyase in chronic diseases.
Khwairakpam AD; Banik K; Girisa S; Shabnam B; Shakibaei M; Fan L; Arfuso F; Monisha J; Wang H; Mao X; Sethi G; Kunnumakkara AB
J Mol Med (Berl); 2020 Jan; 98(1):71-95. PubMed ID: 31858156
[TBL] [Abstract][Full Text] [Related]
14. miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Xin M; Qiao Z; Li J; Liu J; Song S; Zhao X; Miao P; Tang T; Wang L; Liu W; Yang X; Dai K; Huang G
Oncotarget; 2016 Jul; 7(28):44252-44265. PubMed ID: 27317765
[TBL] [Abstract][Full Text] [Related]
15. Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle.
Verschueren KHG; Blanchet C; Felix J; Dansercoer A; De Vos D; Bloch Y; Van Beeumen J; Svergun D; Gutsche I; Savvides SN; Verstraete K
Nature; 2019 Apr; 568(7753):571-575. PubMed ID: 30944476
[TBL] [Abstract][Full Text] [Related]
16. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076.
Pearce NJ; Yates JW; Berkhout TA; Jackson B; Tew D; Boyd H; Camilleri P; Sweeney P; Gribble AD; Shaw A; Groot PH
Biochem J; 1998 Aug; 334 ( Pt 1)(Pt 1):113-9. PubMed ID: 9693110
[TBL] [Abstract][Full Text] [Related]
17. ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme.
Gribble AD; Dolle RE; Shaw A; McNair D; Novelli R; Novelli CE; Slingsby BP; Shah VP; Tew D; Saxty BA; Allen M; Groot PH; Pearce N; Yates J
J Med Chem; 1996 Aug; 39(18):3569-84. PubMed ID: 8784456
[TBL] [Abstract][Full Text] [Related]
18. Targeting mitochondrial citrate transport in breast cancer cell lines.
Ozkaya AB; Ak H; Atay S; Aydin HH
Anticancer Agents Med Chem; 2015; 15(3):374-81. PubMed ID: 25511512
[TBL] [Abstract][Full Text] [Related]
19. ATP-citrate lyase is essential for high glucose-induced histone hyperacetylation and fibrogenic gene upregulation in mesangial cells.
Deb DK; Chen Y; Sun J; Wang Y; Li YC
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F423-F429. PubMed ID: 28490526
[TBL] [Abstract][Full Text] [Related]
20. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
Migita T; Narita T; Nomura K; Miyagi E; Inazuka F; Matsuura M; Ushijima M; Mashima T; Seimiya H; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y
Cancer Res; 2008 Oct; 68(20):8547-54. PubMed ID: 18922930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
